Premium
Trisomy 8 in Philadelphia‐negative cells during imatinib therapy
Author(s) -
Bernardeschi P.,
Fiorentini G.,
Rossi S.,
Dentico P.,
Simi P.,
Guidi S.
Publication year - 2004
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20133
Subject(s) - trisomy , imatinib , medicine , philadelphia chromosome , trisomy 8 , imatinib mesylate , oncology , cancer research , genetics , karyotype , chromosomal translocation , biology , chromosome , gene , myeloid leukemia
Targeted therapy with imatinib selectively suppresses Philadelphia‐positive cells in chronic myeloid leukemia cells, with reappearance of apparently normal hemopoiesis in a considerable number of patients. Recently, clonal abnormalities have been observed in Philadelphia‐negative cells during imatinib therapy, the biologic and prognostic significance of which is actually unknown. A case of trisomy 8 occurring in Philadelphia‐negative cells, which was treated by bone marrow transplantation, is reported. Chromosomal abnormalities in Philadelphia‐negative cells do not seem to herald disease transformation, but the long‐term prognosis may be influenced by an increased incidence of myelodysplasia in younger patients. Am. J. Hematol. 77:88–89, 2004. © 2004 Wiley‐Liss, Inc.